Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MERTK | Q12866 | 7/20 | 0.60 |
| ▸ | TYRO3 | Q06418 | 5/20 | 0.55 |
| ▸ | GAS6 | Q14393 | 4/20 | 0.55 |
| ▸ | PSMD14 | O00487 | 1/20 | 0.48 |
| ▸ | STAMBP | O95630 | 1/20 | 0.48 |
| ▸ | FLT3 | P36888 | 3/20 | 0.48 |
| ▸ | AXL | P30530 | 1/20 | 0.46 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.45 |
| ▸ | JUN | P05412 | 1/20 | 0.45 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.45 |
| ▸ | MEN1 | O00255 | 1/20 | 0.45 |
| ▸ | PARP1 | P09874 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL558897 | 1.00 | MERTK (0.60) | MERTKTYRO3GAS6PSMD14STAMBP | |
| SCHEMBL2261720 | 0.84 | KDM4E (0.49) | MERTKTYRO3GAS6FLT3AXL | |
| SCHEMBL559858 | 0.84 | KDM4E (0.49) | MERTKTYRO3GAS6FLT3AXL | |
| SCHEMBL559345 | 0.84 | MAPK10 (0.52) | MERTKTYRO3GAS6FLT3AXL | |
| SCHEMBL559344 | 0.84 | MAPK10 (0.52) | MERTKTYRO3GAS6FLT3AXL | |
| SCHEMBL2262153 | 0.83 | JUN (0.45) | MERTKTYRO3GAS6FLT3AXL | |
| SCHEMBL559306 | 0.83 | JUN (0.45) | MERTKTYRO3GAS6FLT3AXL | |
| SCHEMBL558976 | 0.83 | MAPK10 (0.44) | MERTKTYRO3GAS6FLT3AXL | |
| SCHEMBL2258369 | 0.83 | MAPK10 (0.44) | MERTKTYRO3GAS6FLT3AXL | |
| SCHEMBL559186 | 0.83 | JUN (0.53) | MERTKTYRO3GAS6FLT3AXL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7998978-B2 | Substituted 2-amino-fused heterocyclic compounds | PFIZER INC. (US) | 2011-08-16 | — | — | US | disclosed |
| US-20100056506-A1 | SUBSTITUTED 2-AMINO-FUSED HETEROCYCLIC COMPOUNDS | PFIZER PRODUCTS INC. (US) | 2010-03-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100056506-A1 | SUBSTITUTED 2-AMINO-FUSED HETEROCYCLIC COMPOUNDS | MAPK1, SLC5A1, ATF1 | MERTK 2882/4885TYRO3 691/4885GAS6 2254/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.